In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest pays AZ $210mm for all rights to Novexel candidate

Executive Summary

Following its concurrently announced acquisition of antibiotics developer Novexel, AstraZeneca has agreed to hand over all rights for Novexel's lead broad-spectrum candidate NXL104 to Forest Laboratories for $210mm. The deal sees AZ both granting and receiving rights through what turns out to be a very complex transaction.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies